[시장보고서]세계의 건선 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 작용기전별, 투여 경로별, 지역별, 경쟁별(2020-2030년)

세계의 건선 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 작용기전별, 투여 경로별, 지역별, 경쟁별(2020-2030년)

Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type of Treatment, By Mechanism of Action, By Route of Administration, By Region & Competition, 2020-2030F

상품코드 : 1738341

리서치사 : TechSci Research

발행일 : 2025년 05월

페이지 정보 : 영문 183 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,165,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,535,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 10,960,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계의 건선 치료제 시장 규모는 2024년에 210억 6,000만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 6.57%로 성장할 전망이며, 예측 기간 종료시에는 큰 시장 규모에 이를 것으로 예측되고 있습니다.

이 시장은 세계의 건선 이환율 증가, 진행중인 치료법의 진보, 보다 효과적이고 맞춤형 치료에 대한 수요 증가에 의해 급속히 발전하고 있습니다. 건선은 붉고 염증을 일으킨 비늘성 피부 병변을 가져오는 만성 자가면역질환으로 세계의 수백만 명이 이환되어 삶의 질에 큰 영향을 미치고 있습니다. 인지도 및 진단 능력이 향상됨에 따라 건선의 특정과 치료는 보다 일반적으로 되고 있습니다. 치료법은 다방면에 걸쳐 외용약, 광선요법, 전신약, 생물학적 제제 등이 있습니다. 특히 생물학적 제제는 유효성과 안전성을 높여 치료의 패러다임을 변혁해 왔습니다. 연구 확대, 헬스케어 정책 지원, 표적 치료에 대한 환자 수요 증가로 건선 치료제 시장은 세계 각 지역에서 승승장구하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	210억 6,000만 달러
시장 규모(2030년)	306억 달러
CAGR(2025-2030년)	6.57%
급성장 부문	경구
최대 시장	북미

시장 성장 촉진요인

건선 유병률 증가

주요 시장 과제

건선 원인 및 유인의 제한적인 이해

주요 시장 동향

생물학적 제제에 따른 치료가 주류

시장 규모 및 예측
- 금액별
시장 점유율 및 예측
- 치료 유형별(생물학적 제제, 저분자 전신성 약제, 열대 요법)
- 작용기전별(TNFα 억제제, PDE4 억제제, 인터루킨 억제제, 기타)
- 투여 경로별(경구, 비경구, 국소)
- 지역별
- 기업별(2024년)
시장 맵

제6장 북미의 건선 치료제 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 건선 치료제 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
유럽 : 국가별 분석
- 독일
- 영국
- 이탈리아
- 프랑스
- 스페인

제8장 아시아태평양의 건선 치료제 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 남미의 건선 치료제 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제10장 중동 및 아프리카의 건선 치료제 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향 및 발전

최근 동향
제품 출시
합병 및 인수

제13장 세계의 건선 치료제 시장 : SWOT 분석

제14장 경쟁 구도

Glanbia Plc
Pfizer Inc.
Bayer AG
Amway Corp.
GlaxoSmithKline plc.
Good Health New Zealand
The Nature's Bounty Co.
NOW Foods
Abbott
Herbalife Nutrition

제15장 전략적 제안

제16장 기업 소개 및 면책사항

AJY

영문 목차

영문목차

Global Psoriasis Drugs Market has been valued at USD 21.06 billion in 2024 and is expected to grow at a CAGR of 6.57% through 2030, reaching significant market size by the end of the forecast period. This market is evolving rapidly, driven by the increasing global incidence of psoriasis, ongoing therapeutic advancements, and rising demand for more effective and personalized treatments. Psoriasis is a chronic autoimmune disorder that results in red, inflamed, and scaly skin lesions, affecting millions of people worldwide and significantly impacting quality of life. As awareness and diagnostic capabilities improve, the identification and treatment of psoriasis are becoming more prevalent. The therapeutic landscape is diverse, spanning topical agents, phototherapy, systemic drugs, and biologic therapies. Biologics, in particular, have transformed the treatment paradigm by offering enhanced efficacy and safety. With expanding research, supportive healthcare policies, and increasing patient demand for targeted treatments, the psoriasis drugs market continues to gain momentum across global regions.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 21.06 Billion
Market Size 2030	USD 30.60 Billion
CAGR 2025-2030	6.57%
Fastest Growing Segment	Oral
Largest Market	North America

Key Market Drivers

Increasing Prevalence of Psoriasis

The rising prevalence of psoriasis globally is a key driver for the market. This autoimmune condition, characterized by an overproduction of skin cells, results in painful, itchy, and inflamed patches. The likelihood of developing psoriasis increases with genetic predisposition, which is being amplified as populations grow and awareness of the disease improves. According to a 2025 NIH report, Spain saw a 43.3% increase in psoriasis cases from 2022, growing from 692,317 to 991,832. This significant rise illustrates the expanding patient base. Moreover, modern environmental and lifestyle factors-such as heightened stress, smoking, poor diet, and exposure to pollution-are contributing to the disease's growing incidence. Enhanced diagnostic practices also play a role, allowing more cases, including milder forms, to be correctly identified and treated. Collectively, these factors are intensifying the demand for innovative and effective treatment options.

Key Market Challenges

Limited Understanding of Psoriasis Causes and Triggers

One of the most significant challenges in managing psoriasis is the limited understanding of its exact causes and triggers. As a multifactorial autoimmune disorder, psoriasis involves complex interactions between genetic, environmental, and immune system factors. The variability in genetic markers among patients complicates the development of universal or targeted therapies. Additionally, triggers such as stress, infections, and certain medications vary widely from person to person, making individualized treatment approaches challenging. This lack of clarity in disease etiology hinders the development of more precise treatments and limits the potential for personalized medicine in psoriasis care. It also poses difficulties for clinicians in predicting flare-ups and selecting optimal therapeutic strategies.

Key Market Trends

Biologic Therapies Dominating Treatment Approaches

A leading trend in the Global Psoriasis Drugs Market is the rising dominance of biologic therapies. These advanced drugs, derived from living organisms, specifically target key immune system pathways responsible for psoriasis, such as cytokines and immune cell receptors. Biologics have shown superior results compared to conventional treatments, offering greater symptom relief and fewer side effects. This has led to a shift in clinical preference, especially for moderate to severe psoriasis cases. Their ability to provide sustained remission has positioned biologics as a mainstay in psoriasis management. The trend is further supported by ongoing drug development and approvals, making these therapies increasingly accessible and expanding the market for targeted biologic solutions.

Key Market Players

Glanbia Plc
Pfizer Inc.
Bayer AG
Amway Corp.
GlaxoSmithKline plc.
Good Health New Zealand
The Nature's Bounty Co.
NOW Foods
Abbott
Herbalife Nutrition

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

Biologic Drugs
Small Molecule Systemic Drugs
Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

TNF Alpha Inhibitors
PDE4 Inhibitors
Interleukin Inhibitors
Others

Psoriasis Drugs Market, By Route of Administration:

Oral
Parenteral
Topical

Psoriasis Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

Global Psoriasis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Route of Administrations
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
- 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
- 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type of Treatment
- 6.2.2. By Mechanism of Action
- 6.2.3. By Route of Administration
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Psoriasis Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type of Treatment
    - 6.3.1.2.2. By Mechanism of Action
    - 6.3.1.2.3. By Route of Administration
- 6.3.2. Canada Psoriasis Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type of Treatment
    - 6.3.2.2.2. By Mechanism of Action
    - 6.3.2.2.3. By Route of Administration
- 6.3.3. Mexico Psoriasis Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type of Treatment
    - 6.3.3.2.2. By Mechanism of Action
    - 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type of Treatment
- 7.2.2. By Mechanism of Action
- 7.2.3. By Route of Administration
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Psoriasis Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type of Treatment
    - 7.3.1.2.2. By Mechanism of Action
    - 7.3.1.2.3. By Route of Administration
- 7.3.2. United Kingdom Psoriasis Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type of Treatment
    - 7.3.2.2.2. By Mechanism of Action
    - 7.3.2.2.3. By Route of Administration
- 7.3.3. Italy Psoriasis Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Type of Treatment
    - 7.3.3.2.2. By Mechanism of Action
    - 7.3.3.2.3. By Route of Administration
- 7.3.4. France Psoriasis Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type of Treatment
    - 7.3.4.2.2. By Mechanism of Action
    - 7.3.4.2.3. By Route of Administration
- 7.3.5. Spain Psoriasis Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type of Treatment
    - 7.3.5.2.2. By Mechanism of Action
    - 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Psoriasis Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type of Treatment
- 8.2.2. By Mechanism of Action
- 8.2.3. By Route of Administration
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Psoriasis Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type of Treatment
    - 8.3.1.2.2. By Mechanism of Action
    - 8.3.1.2.3. By Route of Administration
- 8.3.2. India Psoriasis Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type of Treatment
    - 8.3.2.2.2. By Mechanism of Action
    - 8.3.2.2.3. By Route of Administration
- 8.3.3. Japan Psoriasis Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type of Treatment
    - 8.3.3.2.2. By Mechanism of Action
    - 8.3.3.2.3. By Route of Administration
- 8.3.4. South Korea Psoriasis Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type of Treatment
    - 8.3.4.2.2. By Mechanism of Action
    - 8.3.4.2.3. By Route of Administration
- 8.3.5. Australia Psoriasis Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type of Treatment
    - 8.3.5.2.2. By Mechanism of Action
    - 8.3.5.2.3. By Route of Administration

9. South America Psoriasis Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type of Treatment
- 9.2.2. By Mechanism of Action
- 9.2.3. By Route of Administration
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Psoriasis Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type of Treatment
    - 9.3.1.2.2. By Mechanism of Action
    - 9.3.1.2.3. By Route of Administration
- 9.3.2. Argentina Psoriasis Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type of Treatment
    - 9.3.2.2.2. By Mechanism of Action
    - 9.3.2.2.3. By Route of Administration
- 9.3.3. Colombia Psoriasis Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type of Treatment
    - 9.3.3.2.2. By Mechanism of Action
    - 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Psoriasis Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type of Treatment
- 10.2.2. By Mechanism of Action
- 10.2.3. By Route of Administration
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Psoriasis Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type of Treatment
    - 10.3.1.2.2. By Mechanism of Action
    - 10.3.1.2.3. By Route of Administration
- 10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type of Treatment
    - 10.3.2.2.2. By Mechanism of Action
    - 10.3.2.2.3. By Route of Administration
- 10.3.3. UAE Psoriasis Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type of Treatment
    - 10.3.3.2.2. By Mechanism of Action
    - 10.3.3.2.3. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Competitive Landscape

14.1. Glanbia Plc
- 14.1.1. Business Overview
- 14.1.2. Mechanism of Action Offerings
- 14.1.3. Recent Developments
- 14.1.4. Key Personnel
- 14.1.5. SWOT Analysis
14.2. Pfizer Inc.
14.3. Bayer AG
14.4. Amway Corp.
14.5. GlaxoSmithKline plc.
14.6. Good Health New Zealand
14.7. The Nature's Bounty Co.
14.8. NOW Foods
14.9. Abbott
14.10. Herbalife Nutrition